Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Clinical Infectious Diseases

Volumn 63, Issue 12, 2016, Pages 1615-1618

  Shields, Ryan K ^a,c   Potoski, Brian A ^a,b,c   Haidar, Ghady ^a   Hao, Binghua ^c   Doi, Yohei ^a   Chen, Liang ^e   Press, Ellen G ^a   Kreiswirth, Barry N ^e   Clancy, Cornelius J ^a,c,d   Nguyen, M Hong ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

carbapenem resistant Enterobacteriaceae; ceftazidime avibactam resistance; Klebsiella pneumoniae carbapenemase

Indexed keywords

AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; CEFTAZIDIME;

ADULT; AGED; ANTIBIOTIC RESISTANCE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84995524184     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw636     Document Type: Article

References (12)

1. Acycaz (Ceftazidime-avibactam). Prescribing information. Cincinnati, Ohio: Forest Pharmaceuticals, Inc, 2016.
2. Shields RK, Clancy CJ, Hao B, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2015; 59:5793-7.
3. Center for Disease Control and Prevention. Healthcare-associated infections (HAIs): CRE definition. Available at: Https://www.cdc.gov/hai/organisms/cre/definition.html. Accessed 6 April 2016.
4. Centers for Disease Control and Prevention/National Healthcare Safety Network Surveillance Definitions for Specific Types of Infections (January 2016). Available at: Http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf. Accessed 1 March.
5. Clancy CJ, Chen L, Shields RK, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 2013; 13:2619-33.
6. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother 2010; 65:490-5.
7. Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 2013; 61:649-72.
8. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014; 20:862-72.
9. Shields RK, Nguyen MH, Potoski BA, et al. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. Antimicrob Agents Chemother 2015; 59:1797-801.
10. Shields RK, Clancy CJ, Press EG, Nguyen MH. Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2016; 60:3187-92.
11. Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidime-avibactam resistance in a KPC-3 expressing Klebsiella pneumoniae. Antimicrob Agents Chemother 2015; 59:6605-7.
12. Livermore DM, Warner M, Jamrozy D, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 2015; 59:5324-30.